Antiphospholipid Antibodies and Stroke Study "APASS"


Phase N/A Results

Summary of Purpose

To evaluate the effect of antiphospholipid antibodies (aPL) positivity on recurrent stroke or thrombotic events.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 16 July 2008.

Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics



  • National Institute for Neurological Disorders and Stroke, NIH

Trial Design

Study uses patients enrolled in WARSS, a randomized and double-blind secondary stroke and death prevention trial comparing aspirin and warfarin in two treatment arms. Antiphospholipid antibody status at baseline on all WARSS enrolled subjects. aPL status will also be documented yearly and at the time of a recurrent thrombo-occlusive event for all aPL(+) patients and one matched aPL(-) patient for each aPL(+) patient to ensure blinding of aPL status at each of the WARSS clinical centers.


Not available